General Updates

August 23, 2026 BSE Limited The National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex, Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 530019 Symbol: JUBLPHARMA Subject: USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sirs, We wish to inform you that USFDA has given its approval for the commercial batch manufacturing of the first product on Line 3 of Jubilant HollisterStier LLC contract manufacturing facility located in Spokane, U.S.A. Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of the company. Date and Time of receipt – August 21, 2026, 12:46 PM (PST) i.e. August 22, 2026, 01:16 AM (IST). We request you to take the same on record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl: As above Jubilant Pharmova announces USFDA approval for its new Isolator based fill and finish line, line three at Contract manufacturing facility, Spokane, U.S.A Noida, Aug 23, 2026: Jubilant Pharmova Limited (“Company”) today announced that USFDA has given approval for the commercial batch manufacturing of the first product on the new Isolator based fill and finish line, Line 3 of Jubilant HollisterStier LLC (JHS)’s contract manufacturing facility located in Spokane, WA. U.S.A. Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of the company. About Jubilant HollisterStier LLC Jubilant HollisterStier is a leading integrated contract manufacturer of sterile injectables (both liquid and lyophilization) and ophthalmics (Ointment, liquid and creams). With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. The services include a full range of support to streamline the manufacturing processes, from process qualifications through commercial release. About Jubilant Pharma Limited Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly- owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 45 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,200 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. About Jubilant Pharmova Limited Jubilant Pharmova Limited is an integrated global pharmaceutical company engaged in Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectable, Contract Research Development and Manufacturing, Generics and Proprietary Novel Drugs businesses. With a network of 45 radiopharmacies in the USA, the Radiopharma business is engaged in manufacturing and supply of radiopharmaceutical products and services. The Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the USA and other markets such as Canada, Europe and Australia. Contract Development and Manufacturing of sterile injectables, with facilities in Spokane, USA, and Montreal, Canada, delivers end-to-end manufacturing solutions, including sterile fill-and-finish injectables (liquid and lyophilized), comprehensive ophthalmic products (liquids, ointments and creams) and ampoules. Contract Research Development and Manufacturing business provides end-to-end drug discovery and development services to the pharmaceutical and biotech industries through three world class research centers (two in India and one in France) and a US FDA approved, Active Pharmaceutical Ingredients manufacturing facility in Nanjangud, Karnataka. The Generics business focuses on development, manufacturing and distribution of Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Proprietary Novel Drugs is an innovative biopharmaceutical business developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova has a team of around 5,500 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com. For more information, please contact: For Investors Siddharth Rangnekar Pankaj Dhawan CDR India Phone: +91 120 436 1105 Phone: +91 97699 19966 E-mail: Pankaj.dhawan@jubl.com E-mail: siddharth@cdr-india.com For Media Jyoti Sharma Sandipan Ghatak Ad Factors PR Phone: +91-98107 76182 Phone: +91 9810519900 E-mail: sandipan.ghatak@jubl.com E-mail: jyoti.sharma@adfactorspr.com Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.